Overview
Patrick Rüdelsheim is a co-founder of 3bio and is based in Gent. Since December 2023 he has served at 3BIO as a director and chief regulatory officer. Between April 2017 and January 2025 he was a director and senior regulatory advisor at ABS-int, and from April 2003 to January 2025 he was owner and general partner of Perseus BVBA.
Earlier, he headed biotechnology regulatory affairs globally at Bayer Crop Science, from 2000 to 2001 and again from 2002 to 2003, and held the same responsibility at AgrEvo GmbH from 1996 to 2000. He was director of regulatory affairs at Plant Genetic Systems from 1990 to 2000, and before that worked as a biotechnology researcher at D.J. VanderHave B.V. from 1988 to 1990.
Rüdelsheim attended Onze-Lieve-Vrouwecollege from 1965 to 1977 and completed a PhD in science and biology at the University of Antwerp in 1987.
Career history
- Founder3BIO
In the news
- Some talks you keep thinking about on the train home. This year's Evelien Kampert lecture at the BVF platform Symposium was one of them. Our co-founder, Patrick Rüdelsheim, who has spent a career on how biosafety handles the rare event and the ordinary one, was honored to be chosen to give this lecture. The title of his talk: "Inner Impact – Over zwarte zwanen en zwaluwen", black swans and swallows. Black swans, the events nobody sees coming, are a structural part of biosafety practice; swallows are the signs worth heeding even
- Fragmented data, complex regulations, time-consuming administration. Most biosafety officers will recognise the list. On 6 October, 3BIO took those three problems to the BVF Platform annual symposium in Driebergen-Rijsenburg (Utrecht). The BVF Platform is the Dutch association of biological safety officers. Biosafety and ABS rarely sit in one place as they do in 3BIO, so we brought them together at the symposium. We included The 3BIO Academy for training that stays current, OrBios for material, equipment, facilities and staffing
- When could gene drives be used in Europe? And are we ready to assess the risks of a potential release? The questions are no longer hypothetical. This new EFSA External Scientific Report brings together what is known so far. It covers possible use cases for the EU, the choice of comparators, the role of ecological modelling and how post-market monitoring could be designed. It also shows how complex the risk assessment process can be. Gene drives are designed to spread across generations and populations, which has raised
- While GMO legislation has long created a patchwork of divergent thresholds and requirements across jurisdictions, the fragmented and protracted approach to New Genomic Techniques adds a further layer of complexity to an already uneven global landscape. Rather than converging on a shared framework, successive national and regional initiatives on NGTs risk deepening the mismatch between legislations, leaving operators to navigate an increasingly confusing regulatory puzzle.
- For most biosafety professionals, the "Guidelines for Research Involving Recombinant DNA Molecules," issued by the U.S. National Institutes of Health, have served as a solid reference for biosafety management for nearly fifty years. The NIH has now published a Request for Comment on a draft NIH Biosafety Policy for Research Involving Biohazards, which would substantially broaden the scope of NIH oversight beyond recombinant and synthetic nucleic acid research to also cover wild-type biological agents, genetically modified organisms
- Excited to be presenting this week at #ECB2026 in Antwerp 🌿 I will be sharing the regulatory and biosafety findings from the EU-funded NYMPHE project — a Horizon Europe initiative developing system-driven bioremediation strategies for contaminated soils, sediments, groundwater, and wastewater across European sites. Our work has explored how existing EU regulatory frameworks — from Directive 2009/41/EC on the contained use of GMOs to the new EU Biotech Act — apply to the broad range of biologics used in environmental remediation,
Related profiles
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.